Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07668635 · ClinicalTrials.gov registry record · Phase 1
Cannabis Effects on Opioid Self-Administration
A Phase 1 study, sponsored by Shanna Babalonis, PhD.
- Not yet
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT07668635: Clinical Trial Phase 1 study, sponsored by Shanna Babalonis, PhD.
NCT07668635 is a Phase 1 study that has not yet begun recruiting, run by Shanna Babalonis, PhD. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07668635, a Phase 1 study, has not yet begun recruiting, sponsored by Shanna Babalonis, PhD.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.
Primary Outcome
Number of drug-choice trials completed for intranasal opioid agonists during self-administration sessions.
Interventions
- DRUG Cannabis
- DRUG Placebo Cannabis
- DRUG Intranasal Opioid Agonist
- DRUG Oral Opioid Agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-07-30 |
| Est. Completion | 2031-07-30 |
| Phase | Phase 1 |
What is known before NCT07668635 opens enrollment
NCT07668635 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 4 interventions - of which Cannabis is the first listed.
NCT07668635 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07668635 about?
NCT07668635 is a clinical study titled "Cannabis Effects on Opioid Self-Administration". The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can ...
What is the current status of trial NCT07668635?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-07-30. Estimated completion is 2031-07-30.
What interventions are being tested in trial NCT07668635?
The interventions under investigation include: Cannabis (DRUG), Placebo Cannabis (DRUG), Intranasal Opioid Agonist (DRUG), Oral Opioid Agonist (DRUG).
Who is sponsoring clinical trial NCT07668635?
This trial is sponsored by Shanna Babalonis, PhD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07668635's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI